Clinic
Sentara Hospitals
Sentara Hospitals was paid $78.52M by Medicaid between Jan 2018 and Dec 2024, across 341 billing codes. Its largest line is 99283, emergency room visit (moderate) — 26% of everything it billed.
33Billing provider infoSENTARA HOSPITALS
HAMPTON, VA 23666
HAMPTON, VA 23666
33aNPI1336109107assigned 03/25/2006
33bProvider typeCardiac Rehabilitation Clinic/Center
28Total paid$78.52M
24GClaims1,978,987
24DCodes billed341
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Cardiac Rehabilitation Clinic/Center providers in Virginia
Rank by total paid#1 of 6
Median peer was paid$52.40M
This provider vs. median1.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HANCOCK, MELINDA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 193,879 | $4.60M | |
| 2019 | 262,815 | $6.96M | |
| 2020 | 238,956 | $9.53M | |
| 2021 | 308,122 | $12.36M | |
| 2022 | 338,136 | $14.40M | |
| 2023 | 391,489 | $18.78M | |
| 2024incomplete | 245,590 | $11.89M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 26% | 128,992 | 108,559 | $20.71M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 70,996 | 57,059 | $11.48M |
| 96361 | Intravenous infusion, hydration; each additional hour | 11% | 30,640 | 22,864 | $8.48M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 8.3% | 41,479 | 36,740 | $6.49M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.9% | 32,440 | 26,309 | $5.43M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.9% | 45,571 | 12,137 | $2.27M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.6% | 10,872 | 9,469 | $2.06M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.4% | 10,271 | 8,861 | $1.91M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.8% | 7,874 | 2,566 | $1.38M |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 3,080 | 2,724 | $755K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 4,337 | 3,711 | $754K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 6,296 | 5,482 | $722K |
329 more codes
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,519 | $703K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 14,756 | $640K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 4,296 | $566K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 11,562 | $527K |
| 97161 | <1% | 4,479 | $467K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 13,642 | $461K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,466 | $459K |
| G0378 | Hospital observation service, per hour | <1% | 1,809 | $442K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,107 | $420K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,860 | $387K |
| 76642 | <1% | 3,669 | $365K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 17,723 | $330K |
| 97162 | <1% | 2,985 | $298K | |
| J3490 | Unclassified drugs | <1% | 226,589 | $295K |
| 10060 | <1% | 2,327 | $290K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 7,213 | $281K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 49,011 | $268K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,819 | $260K |
| 12001 | <1% | 1,223 | $259K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,445 | $254K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,889 | $254K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 21,744 | $244K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,410 | $229K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,044 | $223K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,595 | $219K |
| 93971 | <1% | 2,597 | $216K | |
| 76830 | Ultrasound, transvaginal | <1% | 2,711 | $211K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 58,992 | $209K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,331 | $200K |
| 76801 | <1% | 4,262 | $189K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 15,280 | $186K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 7,559 | $179K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,297 | $177K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 351 | $173K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,727 | $158K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 18,895 | $153K |
| 0240U | <1% | 2,166 | $122K | |
| 29125 | <1% | 838 | $122K | |
| 94060 | <1% | 2,143 | $113K | |
| 11045 | <1% | 148 | $113K | |
| 70486 | <1% | 1,585 | $113K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 575 | $109K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 47,718 | $108K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 5,067 | $103K |
| 97016 | <1% | 3,553 | $103K | |
| 80053 | Comprehensive metabolic panel | <1% | 30,170 | $101K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,578 | $100K |
| 76536 | <1% | 892 | $99K | |
| 72141 | <1% | 453 | $95K | |
| 71250 | <1% | 1,352 | $93K | |
| 70491 | <1% | 534 | $91K | |
| 93970 | <1% | 780 | $89K | |
| 93017 | <1% | 786 | $88K | |
| 12011 | <1% | 425 | $86K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 2,967 | $83K |
| 77065 | Tomosynthesis, mammo | <1% | 2,187 | $82K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 3,730 | $82K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 583 | $81K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 863 | $80K |
| 80047 | <1% | 13,000 | $80K | |
| 77066 | Tomosynthesis, mammo | <1% | 2,210 | $67K |
| 19083 | <1% | 64 | $58K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 10,290 | $57K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 2,555 | $56K |
| 73562 | <1% | 6,547 | $51K | |
| 90715 | <1% | 2,761 | $49K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 22,281 | $48K |
| 73130 | <1% | 4,969 | $47K | |
| 93458 | <1% | 33 | $46K | |
| 72110 | <1% | 3,193 | $46K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 31,770 | $46K |
| 94729 | <1% | 1,783 | $45K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 79,669 | $44K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 46,343 | $43K |
| 83880 | <1% | 6,160 | $42K | |
| 12002 | <1% | 203 | $41K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,027 | $40K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 198 | $40K |
| G0422 | Intensive cardiac rehabilitation; with or without continuous ecg monitoring with exercise, per session | <1% | 271 | $40K |
| 94726 | <1% | 1,548 | $39K | |
| 93976 | <1% | 777 | $39K | |
| 90935 | Hemodialysis procedure with single evaluation by a physician | <1% | 135 | $37K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 4,273 | $36K |
| 93798 | <1% | 811 | $35K | |
| 73030 | <1% | 4,647 | $35K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 2,880 | $35K |
| 97116 | <1% | 2,088 | $35K | |
| 73630 | <1% | 5,685 | $35K | |
| 74018 | <1% | 3,073 | $33K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 6,030 | $33K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 7,709 | $32K |
| 85379 | <1% | 7,577 | $31K | |
| 87040 | <1% | 6,409 | $31K | |
| 77336 | <1% | 539 | $31K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 32 | $30K |
| 84484 | <1% | 28,411 | $29K | |
| 64493 | <1% | 28 | $29K | |
| 97113 | <1% | 680 | $28K | |
| 85027 | <1% | 14,738 | $27K | |
| 97165 | <1% | 349 | $27K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 179 | $27K |
| 80076 | <1% | 13,968 | $26K | |
| 72050 | <1% | 1,952 | $26K | |
| 76770 | <1% | 294 | $26K | |
| 96376 | <1% | 11,322 | $25K | |
| 71045 | Radiologic examination, chest; single view | <1% | 12,238 | $24K |
| 82962 | <1% | 17,953 | $24K | |
| 84703 | <1% | 18,105 | $24K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 121 | $23K |
| 29515 | <1% | 163 | $22K | |
| 59050 | <1% | 98 | $22K | |
| 97597 | <1% | 1,099 | $21K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 30 | $20K |
| 73610 | <1% | 4,434 | $20K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 214 | $19K |
| 73221 | <1% | 101 | $18K | |
| 73502 | <1% | 2,665 | $17K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,238 | $17K |
| 77080 | <1% | 328 | $17K | |
| 76870 | <1% | 203 | $17K | |
| 97750 | <1% | 736 | $16K | |
| 81025 | <1% | 32,351 | $15K | |
| 29130 | <1% | 99 | $15K | |
| 81001 | <1% | 53,664 | $15K | |
| 85014 | <1% | 8,830 | $15K | |
| 71271 | <1% | 133 | $15K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 13 | $14K |
| 81003 | <1% | 24,654 | $13K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 18,637 | $13K |
| 73110 | <1% | 2,445 | $11K | |
| 73700 | <1% | 98 | $11K | |
| 95811 | <1% | 12 | $10K | |
| 73564 | <1% | 891 | $10K | |
| 97166 | <1% | 115 | $9K | |
| 73140 | <1% | 2,246 | $9K | |
| 64494 | <1% | 27 | $9K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,733 | $9K |
| 72040 | <1% | 488 | $9K | |
| 85610 | <1% | 5,858 | $9K | |
| 80061 | Lipid panel | <1% | 1,422 | $8K |
| 36415 | Collection of venous blood by venipuncture | <1% | 9,045 | $8K |
| 86850 | <1% | 1,898 | $8K | |
| 84702 | <1% | 6,542 | $7K | |
| 73080 | <1% | 1,172 | $7K | |
| 92523 | <1% | 29 | $7K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 8,210 | $7K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 13,523 | $7K |
| 70496 | <1% | 27 | $7K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 28,807 | $7K |
| 72100 | <1% | 847 | $7K | |
| 84145 | <1% | 1,505 | $6K | |
| 80143 | <1% | 1,157 | $6K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,411 | $6K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 12,704 | $6K |
| 83690 | <1% | 22,025 | $6K | |
| 82553 | <1% | 1,860 | $6K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 21,722 | $6K |
| 82565 | <1% | 3,083 | $5K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 380 | $5K |
| 73590 | <1% | 1,197 | $5K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 24,371 | $5K |
| 72072 | <1% | 246 | $5K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,022 | $5K |
| 83605 | <1% | 6,367 | $5K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 12 | $5K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 6,972 | $4K |
| 83735 | <1% | 5,754 | $4K | |
| 87210 | <1% | 13,044 | $4K | |
| 36430 | <1% | 17 | $4K | |
| 76937 | <1% | 334 | $4K | |
| 93242 | <1% | 43 | $4K | |
| 86901 | <1% | 3,678 | $4K | |
| 74183 | <1% | 13 | $3K | |
| 77062 | <1% | 84 | $3K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 10,049 | $3K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,873 | $3K |
| 85018 | <1% | 1,163 | $3K | |
| 80179 | <1% | 1,075 | $3K | |
| G0423 | Intensive cardiac rehabilitation; with or without continuous ecg monitoring; without exercise, per session | <1% | 264 | $3K |
| 87081 | <1% | 4,586 | $3K | |
| 87631 | <1% | 159 | $3K | |
| 70498 | <1% | 29 | $3K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 1,486 | $3K |
| 72120 | <1% | 53 | $3K | |
| 87186 | <1% | 4,312 | $2K | |
| 82077 | <1% | 7,517 | $2K | |
| 85730 | <1% | 2,187 | $2K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 1,636 | $2K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 9,617 | $2K |
| 74019 | <1% | 326 | $2K | |
| 73660 | <1% | 543 | $2K | |
| 86140 | <1% | 449 | $2K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 31 | $2K |
| 73090 | <1% | 588 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,416 | $2K |
| 93243 | <1% | 43 | $2K | |
| 87077 | <1% | 6,536 | $2K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 12 | $2K |
| 93880 | <1% | 29 | $2K | |
| 71101 | <1% | 886 | $2K | |
| 86900 | <1% | 3,675 | $2K | |
| 74022 | <1% | 862 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,594 | $2K |
| J2704 | Injection, propofol, 10 mg | <1% | 4,513 | $2K |
| 77061 | <1% | 47 | $2K | |
| 77417 | <1% | 67 | $2K | |
| 90686 | <1% | 323 | $2K | |
| 87205 | <1% | 1,181 | $2K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,347 | $1K |
| 85652 | <1% | 791 | $1K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,722 | $1K |
| 87634 | <1% | 86 | $1K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 8,600 | $1K |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 547 | $1K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 8,810 | $1K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 6,169 | $963.19 |
| 92610 | <1% | 15 | $959.97 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 12,278 | $944.68 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,898 | $898.50 |
| 87070 | <1% | 1,153 | $845.41 | |
| 97014 | <1% | 44 | $821.49 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 3,739 | $782.94 |
| C1769 | Guide wire | <1% | 1,434 | $722.06 |
| 80164 | <1% | 187 | $706.99 | |
| 82550 | <1% | 1,120 | $684.98 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 3,724 | $644.31 |
| 94799 | <1% | 455 | $578.90 | |
| 88307 | <1% | 33 | $537.23 | |
| 96367 | <1% | 51 | $534.59 | |
| 77300 | <1% | 27 | $448.93 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 4,129 | $439.14 |
| 82803 | <1% | 1,378 | $436.26 | |
| 80177 | <1% | 87 | $425.48 | |
| 73552 | <1% | 150 | $421.74 | |
| 88304 | <1% | 380 | $343.98 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 291 | $332.74 |
| 84550 | <1% | 198 | $319.35 | |
| 70360 | <1% | 100 | $317.95 | |
| 82607 | <1% | 21 | $292.62 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,665 | $291.24 |
| 73560 | <1% | 16 | $276.64 | |
| G0008 | Administration of influenza virus vaccine | <1% | 865 | $275.85 |
| 87593 | <1% | 15 | $270.76 | |
| 88342 | <1% | 184 | $260.72 | |
| 82728 | <1% | 46 | $252.06 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,164 | $239.27 |
| 80320 | <1% | 68 | $226.18 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 497 | $216.49 |
| 84100 | <1% | 1,011 | $213.46 | |
| 73060 | <1% | 50 | $197.57 | |
| 90694 | <1% | 111 | $186.23 | |
| 85045 | <1% | 750 | $156.19 | |
| 93922 | <1% | 17 | $138.22 | |
| 86780 | <1% | 30 | $137.47 | |
| 97163 | <1% | 15 | $117.92 | |
| 86803 | <1% | 13 | $107.90 | |
| J1815 | Injection, insulin, per 5 units | <1% | 810 | $100.16 |
| 85046 | <1% | 1,046 | $87.11 | |
| 82310 | <1% | 585 | $82.80 | |
| 82746 | <1% | 13 | $77.99 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 295 | $74.55 |
| J3535 | Drug administered through a metered dose inhaler | <1% | 188 | $69.89 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,461 | $68.26 |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 589 | $67.04 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 708 | $62.78 |
| 82272 | <1% | 821 | $52.84 | |
| 84439 | <1% | 14 | $51.39 | |
| 84520 | <1% | 138 | $48.54 | |
| 82330 | <1% | 229 | $46.79 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 726 | $41.48 |
| 83550 | <1% | 12 | $36.06 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 307 | $32.32 |
| 83540 | <1% | 12 | $27.22 | |
| 36000 | <1% | 14 | $26.88 | |
| 36416 | <1% | 107 | $25.85 | |
| 87340 | <1% | 69 | $24.60 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 220 | $24.00 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 501 | $23.70 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,408 | $23.57 |
| 87807 | <1% | 255 | $21.71 | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 1,155 | $17.90 |
| 83615 | <1% | 48 | $16.97 | |
| 82947 | <1% | 178 | $15.08 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 156 | $14.33 |
| 82374 | <1% | 52 | $10.34 | |
| 82009 | <1% | 520 | $9.64 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 103 | $7.40 |
| J0456 | Injection, azithromycin, 500 mg | <1% | 51 | $5.35 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 162 | $3.98 |
| 90653 | <1% | 85 | $3.66 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 131 | $2.39 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 13 | $2.25 |
| 90756 | <1% | 51 | $1.86 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 201 | $0.72 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 32 | $0.26 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 222 | $0.04 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 1,282 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 729 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 135 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 549 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 394 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 1,076 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 53 | $0.00 |
| 84132 | 0% | 63 | $0.00 | |
| J1817 | Insulin for administration through dme (i.e., insulin pump) per 50 units | 0% | 196 | $0.00 |
| 87529 | 0% | 14 | $0.00 | |
| A4648 | Tissue marker, implantable, any type, each | 0% | 305 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 574 | $0.00 |
| 87255 | 0% | 24 | $0.00 | |
| 86308 | 0% | 15 | $0.00 | |
| 90674 | 0% | 43 | $0.00 | |
| A9540 | Technetium tc-99m macroaggregated albumin, diagnostic, per study dose, up to 10 millicuries | 0% | 13 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 12 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 130 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 564 | $0.00 |
| C1729 | Catheter, drainage | 0% | 533 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 97 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 224 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 194 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 331 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 208 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 14 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 366 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 237 | $0.00 |
| 86923 | 0% | 34 | $0.00 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 71 | $0.00 |
| 84295 | 0% | 35 | $0.00 | |
| J0736 | Injection, clindamycin phosphate, 300 mg | 0% | 30 | $0.00 |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHANCOCK, MELINDA (CFO)
| Provider | Location | Paid |
|---|---|---|
| Sentara Hospitals | Norfolk, VA | $88.20M |
| Sentara Hospitals | Norfolk, VA | $79.69M |
| Potomac Hospital Corporation of Prince William | Woodbridge, VA | $59.17M |
| Sentara Hospitals | Suffolk, VA | $57.85M |
| Sentara RMH Medical Center | Harrisonburg, VA | $52.95M |
| Sentara Hospitals | Virginia Beach, VA | $52.40M |
| Sentara Princess Anne Hospital | Virginia Beach, VA | $37.50M |
| Martha Jefferson Hospital | Charlottesville, VA | $26.95M |
| Halifax Regional Hospital, INC. | South Boston, VA | $23.28M |
| Sentara Hospitals | Williamsburg, VA | $21.89M |
| Sentara Albemarle Regional Medical Center | Elizabeth City, NC | $13.82M |
| Sentara Reference Lab Solutions, LLC | Norfolk, VA | $4.74M |
| Halifax Regional Hospital, INC | South Boston, VA | $1.61M |
| Halifax Regional Hospital, INC | Nathalie, VA | $348K |
| Halifax Regional Hospital, INC | South Boston, VA | $336K |
| Halifax Regional Hospital, INC | Chase City, VA | $298K |
| Halifax Regional Hospital, INC | Clarksville, VA | $265K |
| Sentara Hospitals | Norfolk, VA | $171K |
| Halifax Regional Hospital, INC | South Boston, VA | $170K |
| Sentara Hospitals | Norfolk, VA | $128K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.